NeuBase Therapeutics Inc (NBSE)
0.378
0.00 (0.00%)
USD |
NASDAQ |
May 17, 16:00
NeuBase Therapeutics Enterprise Value: -11.16M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 17, 2024 | -11.16M |
May 16, 2024 | -11.16M |
May 15, 2024 | -11.16M |
May 14, 2024 | -11.16M |
May 13, 2024 | -11.16M |
May 10, 2024 | -11.16M |
May 09, 2024 | -11.11M |
May 08, 2024 | -11.05M |
May 07, 2024 | -11.08M |
May 06, 2024 | -11.04M |
May 03, 2024 | -11.06M |
May 02, 2024 | -11.03M |
May 01, 2024 | -11.02M |
April 30, 2024 | -11.02M |
April 29, 2024 | -11.01M |
April 26, 2024 | -10.93M |
April 25, 2024 | -10.92M |
April 24, 2024 | -11.00M |
April 23, 2024 | -11.00M |
April 22, 2024 | -11.00M |
April 19, 2024 | -10.97M |
April 18, 2024 | -10.95M |
April 17, 2024 | -11.00M |
April 16, 2024 | -11.07M |
April 15, 2024 | -11.01M |
Date | Value |
---|---|
April 12, 2024 | -10.93M |
April 11, 2024 | -11.04M |
April 10, 2024 | -11.07M |
April 09, 2024 | -11.10M |
April 08, 2024 | -11.05M |
April 05, 2024 | -11.08M |
April 04, 2024 | -10.97M |
April 03, 2024 | -10.90M |
April 02, 2024 | -10.98M |
April 01, 2024 | -10.93M |
March 28, 2024 | -10.89M |
March 27, 2024 | -10.95M |
March 26, 2024 | -10.78M |
March 25, 2024 | -8.841M |
March 22, 2024 | -8.729M |
March 21, 2024 | -8.729M |
March 20, 2024 | -8.580M |
March 19, 2024 | -8.729M |
March 18, 2024 | -8.804M |
March 15, 2024 | -8.957M |
March 14, 2024 | -9.177M |
March 13, 2024 | -9.135M |
March 12, 2024 | -9.028M |
March 11, 2024 | -9.073M |
March 08, 2024 | -9.100M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-17.12M
Minimum
Dec 19 2022
260.32M
Maximum
Jun 18 2020
57.03M
Average
33.00M
Median
Dec 29 2021
Enterprise Value Benchmarks
Ampio Pharmaceuticals Inc | -3.815M |
Stoke Therapeutics Inc | 545.89M |
ABVC BioPharma Inc | 12.37M |
MAIA Biotechnology Inc | 64.01M |
Aprea Therapeutics Inc | -3.753M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -1.821M |
Total Expenses (Quarterly) | 1.591M |
EPS Diluted (Quarterly) | -0.66 |
Earnings Yield | -2.04K% |